Udit Verma, MD
Advertisement
Articles by Udit Verma, MD
Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Udit Verma on Managing Regorafenib Side Effects in CRCPublished: July 22nd 2016 | Updated:
Dr. Udit Verma on Regorafenib in Patients With mCRCPublished: April 13th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5